search
Back to results

Lifestyle Patterns and Glycemic Control

Primary Purpose

Pre-diabetes

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Fixed Schedule
Sponsored by
Columbia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Pre-diabetes

Eligibility Criteria

35 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Pre-diabetic kg/m2 (hemoglobin A1c 5.7-6.4%)
  • 35 years or older
  • BMI between 25-39.9 kg/m2
  • Sleep duration ≥6 hours a night assessed with wrist actigraphy (for 14 nights)
  • Variable bedtime, SD≥45 minutes.

Exclusion Criteria:

  • Chronic Kidney Disease (GFR<60)
  • Uncontrolled hypertension (≥160/100 mmHg)
  • Obstructive Sleep Apnea
  • Psychiatric or neurological disorder
  • Prevalent cardiovascular disease
  • Dyslipidemia (triglycerides≥200 mg/dL)
  • Medications that affect insulin sensitivity, glucose concentrations, and body weight
  • Non-day or rotating shift workers
  • Travel across time zones
  • Active participation in weight loss program or within past 3 months
  • Current or past alcohol/drug abuse

Sites / Locations

  • Columbia University Irving Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Variable Schedule

Fixed Schedule

Arm Description

Participants randomized to Variable Schedule (VS) will be asked to maintain their usual habits for 12 weeks.

Participants randomized to Fixed Schedule (FS) will be asked to stabilize their lifestyle behaviors for 12 weeks.

Outcomes

Primary Outcome Measures

Adipose Tissue Measurement - Total
Measuring total adiposity. Measured by MRI, includes both subcutaneous and visceral adipose tissue.
Adipose Tissue Measurement - Subcutaneous
Measurement of subcutaneous adiposity using MRI.
Adipose Tissue Measurement - Visceral
Measurement of visceral adiposity using MRI.
Glucose Area Under Curve
Testing glycemic control.The primary outcome variable is glucose under the curve during the oral glucose tolerance test.
Mean Amplitude of Glycemic Excursion and Standard Deviation of Mean Glucose
Testing glucose variability. The primary outcome variables are mean amplitude of glucose excursion and standard deviation of average glucose.

Secondary Outcome Measures

Liver Fat Content
This is to assess liver fat measured by MRS and MRI in %.
Disposition Index
This is to assess disposition index, measured using HOMA-IR. The disposition index is the product of the insulogenic index and homeostatic model of assessment for insulin resistance.
Short-term Change in Glycemia
Assessing whether short-term glycemia is changed by measuring fructosamine using two-sample t-tests.
Endothelial cell inflammation (sub-set, n≤10)
NF-κB nuclear fluorescence area for pilot study. This component of the study is completed and measures are no longer collected as of 08/15/2023.
White blood cells
Leukocytes and neutrophils
Long-term Change in Glycemia
Assessing whether long-term glycemia is changed by measuring hemoglobin A1c using two-sample t-tests.
Endothelial cell oxidative stress (sub-set, n≤10)
redox sensitive fluorogenic probe fluorescence intensity for pilot study. This component of the study is completed and measures are no longer collected as of 08/15/2023.

Full Information

First Posted
January 25, 2022
Last Updated
August 15, 2023
Sponsor
Columbia University
Collaborators
Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT05224986
Brief Title
Lifestyle Patterns and Glycemic Control
Official Title
Lifestyle Patterns and Glycemic Control
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 19, 2022 (Actual)
Primary Completion Date
June 1, 2024 (Anticipated)
Study Completion Date
June 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Columbia University
Collaborators
Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of the proposed study is to evaluate the feasibility and initial efficacy of stabilizing lifestyle behaviors to improve glucose control and body composition in patients with pre-diabetes. The investigator proposes that following stable lifestyle behaviors will improve patients' glucose control, body composition, and liver fat. The results from this study has the potential to impact clinical practice and patient care.
Detailed Description
Variability in lifestyle behaviors has been associated with adverse health, specifically poor glucose control. The project proposes to test whether reducing this variability improves glycemia in patients with pre-diabetes. If successful, this simple positive lifestyle message to keep stable behaviors has the potential to improve the health of millions of adults worldwide. This project will enroll participants with pre-diabetes who have erratic lifestyle behaviors and randomize them to either maintain their usual habits (control group) or stabilize their behaviors (stability group). Both groups will be followed for 12 weeks. Before the start of the 12-week period, all participants will track their sleep for 2 weeks and will wear a glucose monitor to measure their glucose levels. At the start and end of the 12-week period, they will come to the research lab to undergo a glucose tolerance test. This test will measure how their body reacts to a glucose load. They will also undergo magnetic resonance imaging and spectroscopy scanning. This scan will provide information on body composition and liver fat content.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pre-diabetes

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A randomized, parallel-arm clinical intervention study to assess the role of variability in lifestyle behaviors on glucose control and body composition in adults with pre-diabetes. The goal is to test whether following a fixed schedule improves glucose control and insulin sensitivity and reduces adiposity compared to those who maintain a variable schedule.
Masking
Outcomes Assessor
Masking Description
Participants will not be blinded to the intervention or purpose of the study but will be told that rest-activity patterns will be examined in the context of well-being and that we will test the influence of these lifestyle patterns on glucose control and body composition. Although the investigators and research assistant directly involved in the conduct of the study cannot be blinded to participant assignment to the intervention or control group, the technicians involved in sample processing and the biostatistician (Dr. Cheng) will be blinded to this information to reduce the risk of bias.
Allocation
Randomized
Enrollment
34 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Variable Schedule
Arm Type
No Intervention
Arm Description
Participants randomized to Variable Schedule (VS) will be asked to maintain their usual habits for 12 weeks.
Arm Title
Fixed Schedule
Arm Type
Experimental
Arm Description
Participants randomized to Fixed Schedule (FS) will be asked to stabilize their lifestyle behaviors for 12 weeks.
Intervention Type
Behavioral
Intervention Name(s)
Fixed Schedule
Intervention Description
Participants will be asked to maintain a fixed schedule for 12 weeks.
Primary Outcome Measure Information:
Title
Adipose Tissue Measurement - Total
Description
Measuring total adiposity. Measured by MRI, includes both subcutaneous and visceral adipose tissue.
Time Frame
12 weeks
Title
Adipose Tissue Measurement - Subcutaneous
Description
Measurement of subcutaneous adiposity using MRI.
Time Frame
12 weeks
Title
Adipose Tissue Measurement - Visceral
Description
Measurement of visceral adiposity using MRI.
Time Frame
12 weeks
Title
Glucose Area Under Curve
Description
Testing glycemic control.The primary outcome variable is glucose under the curve during the oral glucose tolerance test.
Time Frame
12 weeks
Title
Mean Amplitude of Glycemic Excursion and Standard Deviation of Mean Glucose
Description
Testing glucose variability. The primary outcome variables are mean amplitude of glucose excursion and standard deviation of average glucose.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Liver Fat Content
Description
This is to assess liver fat measured by MRS and MRI in %.
Time Frame
12 weeks
Title
Disposition Index
Description
This is to assess disposition index, measured using HOMA-IR. The disposition index is the product of the insulogenic index and homeostatic model of assessment for insulin resistance.
Time Frame
12 weeks
Title
Short-term Change in Glycemia
Description
Assessing whether short-term glycemia is changed by measuring fructosamine using two-sample t-tests.
Time Frame
Baseline, up to 12 weeks
Title
Endothelial cell inflammation (sub-set, n≤10)
Description
NF-κB nuclear fluorescence area for pilot study. This component of the study is completed and measures are no longer collected as of 08/15/2023.
Time Frame
Baseline, 12 weeks
Title
White blood cells
Description
Leukocytes and neutrophils
Time Frame
Baseline, 12 weeks
Title
Long-term Change in Glycemia
Description
Assessing whether long-term glycemia is changed by measuring hemoglobin A1c using two-sample t-tests.
Time Frame
Baseline, 12 weeks
Title
Endothelial cell oxidative stress (sub-set, n≤10)
Description
redox sensitive fluorogenic probe fluorescence intensity for pilot study. This component of the study is completed and measures are no longer collected as of 08/15/2023.
Time Frame
Baseline, 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pre-diabetic kg/m2 (hemoglobin A1c 5.7-6.4%) 35 years or older BMI between 25-39.9 kg/m2 Sleep duration ≥6 hours a night assessed with wrist actigraphy (for 14 nights) Variable bedtime, SD≥45 minutes. Exclusion Criteria: Chronic Kidney Disease (GFR<60) Uncontrolled hypertension (≥160/100 mmHg) Obstructive Sleep Apnea Psychiatric or neurological disorder Prevalent cardiovascular disease Dyslipidemia (triglycerides≥200 mg/dL) Medications that affect insulin sensitivity, glucose concentrations, and body weight Non-day or rotating shift workers Travel across time zones Active participation in weight loss program or within past 3 months Current or past alcohol/drug abuse
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marie-Pierre St-Onge
Phone
212-851-5578
Email
ms2554@cumc.columbia.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Lara Bond
Phone
(917) 581-4637
Email
lsb2173@cumc.columbia.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie-Pierre St-Onge
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Blandine Laferrere
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Columbia University Irving Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie-Pierre St-Onge, PhD
Email
ms2554@cumc.columbia.edu
First Name & Middle Initial & Last Name & Degree
Lara Bond
Phone
9175814637
Email
lsb2173@cumc.columbia.edu
First Name & Middle Initial & Last Name & Degree
Marie-Pierre St-Onge

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Lifestyle Patterns and Glycemic Control

We'll reach out to this number within 24 hrs